首页> 外文期刊>Liver international : >Cardiovascular risk factors following orthotopic liver transplantation: Predisposing factors, incidence and management
【24h】

Cardiovascular risk factors following orthotopic liver transplantation: Predisposing factors, incidence and management

机译:原位肝移植后心血管危险因素:诱发因素,发生率和管理

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Liver transplantation is the standard of care for acute and chronic causes of end-stage liver disease. Advances in medical therapy and surgical techniques have led to improvement of patient and graft survival rates following orthotopic liver transplantation. However, the prevalence of post-transplant cardiovascular complications has been rising with increased life expectancy after liver transplantation. Aims: To determine the incidences, risk factors, and treatment for hypertension, hyperlipidaemia, diabetes, and obesity in the post-liver transplantation population. Methods: We performed a review of relevant studies available on the PubMed database that provided information on the incidence, risk factors and treatment for cardiovascular complications that develop in the post-liver transplantation population. Results: Current immunosuppressive agents have improved patient and graft survival rates. However, long-term exposure to these agents has been associated with development of systemic and metabolic complications including hypertension, hyperlipidaemia, diabetes mellitus and obesity. Cardiovascular disease remains one of the most common causes of death in liver transplant patients with functional grafts. Conclusions: Liver transplant recipients have a higher risk of cardiovascular complications compared with the nontransplant population. Post-transplant cardiac risk stratification and aggressive treatment of cardiovascular complications, including modification of risk factors and tailoring of immunosuppressive regimen, is imperative to prevent serious complications.
机译:背景:肝移植是终末期肝病急,慢性原因的护理标准。药物治疗和外科手术技术的进步已导致原位肝移植术后患者和移植物存活率的提高。然而,随着肝移植后预期寿命的增加,移植后心血管并发症的患病率正在上升。目的:确定肝移植后人群中高血压,高血脂症,糖尿病和肥胖的发生率,危险因素和治疗方法。方法:我们对PubMed数据库上可用的相关研究进行了回顾,该研究提供了有关肝移植后人群发生的心血管并发症的发生率,危险因素和治疗方法的信息。结果:目前的免疫抑制剂可提高患者和移植物的存活率。但是,长期接触这些药物与全身和代谢并发症(包括高血压,高血脂症,糖尿病和肥胖症)的发展有关。在具有功能性移植物的肝移植患者中,心血管疾病仍然是最常见的死亡原因之一。结论:与非移植人群相比,肝移植患者发生心血管并发症的风险更高。移植后心脏风险分层和积极治疗心血管并发症,包括改变危险因素和调整免疫抑制方案,对于预防严重并发症至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号